Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.
Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.
NO
INDIRECT
ATG does not target HLA-DR; it binds multiple T-cell antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, not by recognizing HLA-DR-expressing cells.
Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.
Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.
NO
INDIRECT
ATG depletes T cells by binding T-cell antigens and inducing complement-dependent lysis and Fc-mediated ADCC/phagocytosis; it does not specifically target HLA class I heavy chain.
Autologous patient-derived CD4+/CD8+ T cells (LMY-920) gene-modified via a non-viral transposon to express a BAFF-ligand chimeric antigen receptor targeting BAFF-R/BR3, TACI, and BCMA to eliminate malignant B cells; dosed at 1–8×10^6 CAR+ cells/kg following lymphodepletion.
Autologous CD4+/CD8+ T cells engineered via a non-viral transposon to express a BAFF-ligand chimeric antigen receptor that binds BAFF family receptors (BAFF-R/BR3, TACI, BCMA) on malignant B cells; antigen engagement activates the CAR T cells to proliferate, secrete cytotoxic mediators/cytokines, and kill the target B cells.
YES
DIRECT
BAFF-ligand CAR-T cells bind BAFF-R on target B cells, become activated, form an immunologic synapse, and kill via perforin/granzyme (and Fas/FasL) cytotoxic pathways.
Autologous patient-derived CD4+/CD8+ T cells (LMY-920) gene-modified via a non-viral transposon to express a BAFF-ligand chimeric antigen receptor targeting BAFF-R/BR3, TACI, and BCMA to eliminate malignant B cells; dosed at 1–8×10^6 CAR+ cells/kg following lymphodepletion.
Autologous CD4+/CD8+ T cells engineered via a non-viral transposon to express a BAFF-ligand chimeric antigen receptor that binds BAFF family receptors (BAFF-R/BR3, TACI, BCMA) on malignant B cells; antigen engagement activates the CAR T cells to proliferate, secrete cytotoxic mediators/cytokines, and kill the target B cells.
YES
DIRECT
BAFF-ligand CAR-T cells bind TACI on target cells, activating the CAR T cells to release perforin/granzymes and induce apoptotic killing of the TACI-expressing cells.
Autologous patient-derived CD4+/CD8+ T cells (LMY-920) gene-modified via a non-viral transposon to express a BAFF-ligand chimeric antigen receptor targeting BAFF-R/BR3, TACI, and BCMA to eliminate malignant B cells; dosed at 1–8×10^6 CAR+ cells/kg following lymphodepletion.
Autologous CD4+/CD8+ T cells engineered via a non-viral transposon to express a BAFF-ligand chimeric antigen receptor that binds BAFF family receptors (BAFF-R/BR3, TACI, BCMA) on malignant B cells; antigen engagement activates the CAR T cells to proliferate, secrete cytotoxic mediators/cytokines, and kill the target B cells.
YES
DIRECT
BAFF-ligand CAR-T cells recognize BCMA on target cells, become activated, and kill via perforin/granzyme cytolysis and death-receptor (e.g., Fas/TRAIL) pathways with cytokine-mediated effects.